Pharmaceuticals

Vasodilators Market Future Outlook Showing Growth Toward $10.38 Billion By 2030

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Vasodilators Market Grow Between 2026 And 2030?

The vasodilators market has seen substantial expansion in recent years. Its valuation is anticipated to climb from $6.76 billion in 2025 to $7.16 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. This historical market progression can be ascribed to a surge in hypertension occurrences, the well-established clinical application of nitrates, advancements in hospital infrastructure, an increasing frequency of heart failure, and the extensive availability of oral vasodilators.

The vasodilators market is projected to experience robust expansion over the coming years. By 2030, this market is forecasted to reach $8.86 billion, exhibiting a compound annual growth rate (CAGR) of 5.5%. This projected growth during the forecast period is fueled by factors such as an aging global population, the increasing prevalence of lifestyle-related diseases, the proliferation of specialty cardiac centers, a heightened emphasis on early diagnosis, and improved availability of cardiovascular medications. Key trends anticipated within this period involve the increasing occurrence of cardiovascular diseases, the wider application of combination drug therapies, the greater acceptance of generic vasodilators, the growth of hospital-based cardiovascular care, and an elevated need for long-term hypertension management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16565&type=smp

What Leading Drivers Are Supporting The Vasodilators Market Expansion?

The future expansion of the vasodilators market is anticipated to be driven by the increasing adoption of sedentary lifestyles. A sedentary lifestyle signifies minimal physical activity and prolonged periods of sitting or lying down, often involving little exercise or movement. This trend is escalating due to modern conveniences like technology, transportation, and office-based jobs, which encourage extended inactivity. Vasodilators are utilized in the context of sedentary lifestyles to enhance blood flow and lower hypertension, thereby reducing cardiovascular risks. For example, the Office for National Statistics, a UK-based government department, reported in July 2023 that over 86.5% of adults in Great Britain indicated making lifestyle adjustments to address environmental concerns, according to survey responses collected from May to June 2023. Thus, the growing adoption of sedentary lifestyles is propelling the growth of the vasodilators market.

Which Segment Classifications Are Used In The Vasodilators Market Segment Analysis?

The vasodilators market covered in this report is segmented –

1) By Type: Arterial Dilators, Venous Dilators, Mixed Dilators

2) By Drugs: Nitroglycerin, Alprostadil, Minoxidil, Sorbitrate, Other Drugs

3) By Indication: Hypertension, Angina, Heart Failure, Other Indications

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End User: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By Arterial Dilators: Calcium Channel Blockers, Nitric Oxide Donors, Potassium Channel Activators

2) By Venous Dilators: Nitrates, Nitrites, Phosphodiesterase Inhibitors (PDE5 Inhibitors)

3) By Mixed Dilators: Alpha-Adrenergic Antagonists, Angiotensin II Receptor Blockers (ARBs), ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

What Trends Are Influencing The Vasodilators Market?

Within the vasodilators market, leading companies are increasingly concentrating on creating novel solutions, including inhaled soluble guanylate cyclase (sGC) activators, aimed at enhancing pulmonary blood flow and more efficiently treating cardiovascular conditions. These inhaled sGC activators function as medications that, upon inhalation, activate the sGC enzyme, leading to blood vessel relaxation and improved circulation, particularly within the lungs. As an example, in September 2024, Roivant Sciences Ltd., a US-based biopharmaceutical and healthcare technology firm, introduced mosliciguat. This is a once-daily, inhaled sGC activator delivered through a dry powder inhaler (DPI), which was developed by its subsidiary Pulmovant. Mosliciguat is designed for direct lung delivery, activates sGC regardless of heme and NO (potentially maintaining its effectiveness even under oxidative stress), and showed average-maximum reductions in pulmonary vascular resistance (PVR) of up to ~38% in pulmonary hypertension patients during a Phase 1b “ATMOS” study. The drug was generally well-received, exhibiting low rates of adverse events, and its pharmacokinetic characteristics allow for once-daily inhalation due to a long half-life and limited systemic exposure. Pulmovant has commenced a global Phase 2 “PHocus” trial involving approximately ~120 patients suffering from PH-ILD to further evaluate its safety and efficacy.

Which Firms Are Contributing To The Vasodilators Market Ecosystem?

Major companies operating in the vasodilators market are Pfizer Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Abbott Laboratories, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Amgen Inc., Gilead Sciences Inc., Biogen, Sun Pharmaceutical Industries Limited

Get The Full Vasodilators Market Report:

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Which Region Is The Leading Market For The Vasodilators Market?

North America was the largest region in the vasodilators market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vasodilators market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Vasodilators Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Browse Through More Reports Similar to the Global Vasodilators Market 2026, By The Business Research Company

Vasodilators Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Peripheral Vasodilator Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report

Vasopressin Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasopressin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795